Moderna mRNA-based drug cut the risk of recurrence or death when combined with immunotherapy Keytruda
“Today’s results highlight the potential of a prolonged benefit of the intismeran autogene and Keytruda combination,” Kyle Holen,…
These 3 Beaten-Down Healthcare Stocks Could Have Farther to Fall
Moderna could tumble once again, if there’s a lack of positive news in its upcoming earnings release. Novo…